Femasys Inc. announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock, totaling approximately $8.0 million in gross proceeds. The net proceeds will be used for expansion, product development, and general corporate purposes. The offering is expected to close on or about August 27, 2025, managed by Jones and Laidlaw & Company (UK) Ltd. The securities are offered via a Registration Statement on Form S-1, declared effective by the SEC on August 25, 2025.

Femasys is a biomedical innovator focusing on accessible fertility and permanent birth control products. Their portfolio includes FemaSeed® Intratubal Insemination and FemBloc® permanent birth control, both showing high effectiveness and patient satisfaction. FemBloc recently received full regulatory approval in Europe and the UK. Femasys is actively commercializing its products in the US and international markets, with the goal of making fertility and birth control more accessible worldwide.

Read more at GlobeNewswire: Femasys Announces Pricing of $8.0 Million Underwritten